AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation status of 'most important'
Number of subjects: 139
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patient gender
Number of subjects: 139
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of recommendations
Number of subjects: 139
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of problems identified by CGA
Number of subjects: 139
Study 1442343 — intervention group
Group type: EXPERIMENTAL
Intervention: sulglycotide
Number of subjects: 9
Study 1442343 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 9
Study 1442343 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 4046137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic-hygienic measures, hypolipidemic agents (mainly probucol and clofibrate), antihypertensive agents (mainly diuretics and beta-blockers)
Number of subjects: 612
Study 4046137 — intervention group
Group type: COMPARATOR
Intervention: Matched high-risk control group (n = 610)
Number of subjects: 612
Study 4046137 — intervention group
Group type: COMPARATOR
Intervention: Low-risk control group (n = 593)
Number of subjects: 612
Study 31315668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0
Study 31315668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30010438 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg morphine (Group 1)
Number of subjects: 60
Study 30010438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg morphine (Group 2)
Number of subjects: 60
Study 30010438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 3)
Number of subjects: 60
Study 26645190 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 139
Study 26645190 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus ciclosporin
Number of subjects: 139
Study 26645190 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus methotrexate
Number of subjects: 139
Study 24106976 — intervention group
Group type: EXPERIMENTAL
Intervention: Family discord present
Number of subjects: 196
Study 22402982 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR tools (physician point‐of‐care alert, counseling template, order set)
Number of subjects: 30
Study 20591813 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete anaemia correction (haemoglobin target of 13 g/dL using darbepoetin alfa)
Number of subjects: 4038
Study 20591813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with a haemoglobin rescue value of 9 g/dL)
Number of subjects: 4038
Study 18042222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 25
Study 18042222 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 25
Study 15949862 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (GCZ)
Number of subjects: 0
Study 15949862 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (GBC)
Number of subjects: 0
Study 12236632 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 20
Study 12236632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10069886 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional home extermination with 2 applications of Abamectin (Avert) insecticide and directed education on cockroach allergen removal
Number of subjects: 265
Study 7618662 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (0.1, 0.3, 0.5, 0.7, 1.0, or 1.5 mg.kg‐1)
Number of subjects: 84
Study 7618662 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 84
Study 2694356 — intervention group
Group type: EXPERIMENTAL
Intervention: Active infrared laser therapy at 904 nm three times weekly for 2 weeks
Number of subjects: 30
Study 2694356 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium
Number of subjects: 30
Study 2694356 — intervention group
Group type: COMPARATOR
Intervention: Dummy laser
Number of subjects: 30
Study 2694356 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment
Number of subjects: 30
Study 122428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg GnRH infusion
Number of subjects: 11
Study 122428 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg GnRH infusion
Number of subjects: 11
Study 122428 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg GnRH infusion
Number of subjects: 11
Study 122428 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study 122428 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg GnRH infusion in boys
Number of subjects: 11
Study 122428 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy in boys
Number of subjects: 11
Study 122428 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg GnRH infusion in men
Number of subjects: 11
Study 31060037 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Resistance Therapy (WRT)
Number of subjects: 22
Study 31060037 — intervention group
Group type: COMPARATOR
Intervention: Open Vocal Tract (OVT) warm-up
Number of subjects: 22
Study 30298560 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of ketoprofen lysine salt (KLS)
Number of subjects: 151
Study 30298560 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of paracetamol/acetaminophen (P)
Number of subjects: 151
Study 30298560 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ketoprofen lysine salt once a day for the first 3 days of activation
Number of subjects: 151
Study 30298560 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 151
Study 29958003 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctive partner, with competition (PWC)
Number of subjects: 90
Study 29958003 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctive partner, no competition (PNC)
Number of subjects: 90
Study 29958003 — intervention group
Group type: COMPARATOR
Intervention: Individual control (IC)
Number of subjects: 90
Study 27358173 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg + 40 mg before PCI)
Number of subjects: 1080
Study 27358173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg twice before PCI)
Number of subjects: 1080
Study 27358173 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5 mg) and ezetimibe (10 mg) twice before PCI
Number of subjects: 1080
Study 27358173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1080
Study 27358173 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1080
Study 24809262 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) immediately after extubation in sequential group
Number of subjects: 53
Study 24809262 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation in control group
Number of subjects: 53
Study 22210658 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg s.c. once weekly for 36-52 weeks
Number of subjects: 84
Study 19296950 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory community treatment
Number of subjects: 0
Study 19296950 — intervention group
Group type: COMPARATOR
Intervention: Service user perspectives
Number of subjects: 0
Study 19296950 — intervention group
Group type: COMPARATOR
Intervention: Family perspectives
Number of subjects: 0
Study 19296950 — intervention group
Group type: COMPARATOR
Intervention: Clinician perspectives
Number of subjects: 0
Study 17609307 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD 20 microg/d
Number of subjects: 2074
Study 17609307 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD 40 microg/d
Number of subjects: 2074
Study 17609307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2074
Study 15179638 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise program (chest-deep water, 1 hour, 3 times a week for 8 weeks)
Number of subjects: 12
Study 15179638 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise program
Number of subjects: 12
Study 15179638 — intervention group
Group type: COMPARATOR
Intervention: Upper-extremity function program (control group, arm and hand exercises while sitting)
Number of subjects: 12
Study 11473071 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement program (clinical practice guidelines, postgraduate education, audit and feedback, templates to register diabetes care, recall system)
Number of subjects: 389
Study 11473071 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no specific intervention mentioned)
Number of subjects: 389
Study 9749737 — intervention group
Group type: EXPERIMENTAL
Intervention: Word 'long'
Number of subjects: 6
Study 9749737 — intervention group
Group type: COMPARATOR
Intervention: Word 'short'
Number of subjects: 6
Study 7831635 — intervention group
Group type: EXPERIMENTAL
Intervention: Baker Norton metered dose inhaler with Volumatic
Number of subjects: 11
Study 7831635 — intervention group
Group type: COMPARATOR
Intervention: Ventolin metered dose inhaler with Volumatic
Number of subjects: 11
Study 3229560 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 99
Study 3229560 — intervention group
Group type: COMPARATOR
Intervention: Psychological placebo
Number of subjects: 99
Study 3229560 — intervention group
Group type: COMPARATOR
Intervention: Own best efforts
Number of subjects: 99
Study 29852092 — intervention group
Group type: EXPERIMENTAL
Intervention: RT5 (5 times weekly)
Number of subjects: 20
Study 29852092 — intervention group
Group type: COMPARATOR
Intervention: RT3 (3 times weekly)
Number of subjects: 20
Study 29852092 — intervention group
Group type: COMPARATOR
Intervention: RT2 (2 times weekly)
Number of subjects: 20
Study 26349445 — intervention group
Group type: EXPERIMENTAL
Intervention: Online video cyberbullying prevention program
Number of subjects: 167
Study 26349445 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 167
Study 25274918 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised forced leg extension assessment pre-operatively and at 6 and 26 weeks post-operatively
Number of subjects: 25
Study 25274918 — intervention group
Group type: COMPARATOR
Intervention: Control group of patients who underwent primary TKR
Number of subjects: 25
Study 21381807 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (cigarette)
Number of subjects: 132
Study 21381807 — intervention group
Group type: COMPARATOR
Intervention: No smoking (control)
Number of subjects: 132
Study 20137762 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin
Number of subjects: 18
Study 20137762 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg everolimus
Number of subjects: 18
Study 20137762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sotrastaurin and everolimus
Number of subjects: 18
Study 20137762 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin with 2 mg everolimus
Number of subjects: 18
Study 17667565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-free anesthesia (80% oxygen, 20% nitrogen)
Number of subjects: 2050
Study 17667565 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-based anesthesia (70% N2O, 30% oxygen)
Number of subjects: 2050
Study 16146460 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative autotransfusion of mediastinal shed blood
Number of subjects: 50
Study 16146460 — intervention group
Group type: COMPARATOR
Intervention: No autotransfusion
Number of subjects: 50
Study 11875167 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release methylphenidate (MPH MR)
Number of subjects: 321
Study 11875167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 7589640 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/d orally for 6 months
Number of subjects: 30
Study 7589640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy with E2 patches and medroxyprogesterone acetate
Number of subjects: 30
Study 7589640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2384192 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-g oral glucose tolerance test (OGTT)
Number of subjects: 0
Study 2384192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure-Plus challenge test (EPCT)
Number of subjects: 0
Study 2384192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tests including hemoglobin, glycosylated hemoglobin, plasma cholesterol, triglycerides, and lipoproteins
Number of subjects: 0
Study 2384192 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine collections for C-peptide and creatinine
Number of subjects: 0
Study 90965 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol daily from admission
Number of subjects: 22
Study 90965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31760780 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 h time in bed (TIB)
Number of subjects: 58
Study 31760780 — intervention group
Group type: COMPARATOR
Intervention: 8 h time in bed (TIB)
Number of subjects: 58
Study 31760780 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed bedtime by 2 hours nightly
Number of subjects: 58
Study 31760780 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring changes in daily affect
Number of subjects: 58
Study 31884935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Dissolving Tablets (FDT) of Febuxostat
Number of subjects: 0
Study 30824248 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Number of subjects: 91
Study 30824248 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study 28219612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FiO2 at 1.0)
Number of subjects: 442
Study 28219612 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FiO2 target 88-95%)
Number of subjects: 442
Study 28219612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3.0%)
Number of subjects: 442
Study 28219612 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%)
Number of subjects: 442
Study 28219612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Number of subjects: 442
Study 28219612 — intervention group
Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 442
Study 27601592 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide-based chemotherapy
Number of subjects: 709
Study 27601592 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-luminal A subtypes
Number of subjects: 709
Study 27601592 — intervention group
Group type: COMPARATOR
Intervention: Control (no systematic treatment)
Number of subjects: 709
Study 24020831 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical HRQoL
Number of subjects: 430
Study 24020831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental HRQoL
Number of subjects: 430
Study 21378175 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) based on 34 type 2 diabetes-associated loci
Number of subjects: 2843
Study 21378175 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 2843
Study 19567380 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect group (Medtronic Insync III Protect device)
Number of subjects: 324
Study 19567380 — intervention group
Group type: COMPARATOR
Intervention: Control group (other Medtronic CRT-D devices)
Number of subjects: 324
Study 17337369 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local infiltration (PLA) with 20 mL of 0.2% ropivacaine diluted with 80 mL of 0.9% saline (total volume 100 mL)
Number of subjects: 30
Study 17337369 — intervention group
Group type: COMPARATOR
Intervention: Postoperative wound infiltration (POW) of 20 mL of 0.2% ropivacaine (40 mg)
Number of subjects: 30
Study 17337369 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local infiltration (PLA)
Number of subjects: 30
Study 17337369 — intervention group
Group type: COMPARATOR
Intervention: Postoperative wound infiltration (POW)
Number of subjects: 30
Study 15529256 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral influenza vaccination
Number of subjects: 0
Study 11297828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg (iv) morphine
Number of subjects: 84
Study 10027666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for two weeks
Number of subjects: 427
Study 10027666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg q.i.d. for two weeks
Number of subjects: 427
Study 10027666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study 10027666 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with oesophagitis
Number of subjects: 427
Study 8085732 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antimicrobials
Number of subjects: 246
Study 8085732 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antipseudomonal agents
Number of subjects: 246
Study 8085732 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 246
Study 2666565 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 30
Study 2666565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 61340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxprenolol
Number of subjects: 5
Study 61340 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 5
Study 61340 — intervention group
Group type: COMPARATOR
Intervention: Control studies (no drug)
Number of subjects: 5
Study 31627041 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 103
Study 31627041 — intervention group
Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 103
Study 28975600 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group (4-min video of Pororo visiting the operating theatre)
Number of subjects: 69
Study 28975600 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 69
Study 28975600 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional information regarding anaesthesia and surgery)
Number of subjects: 69
Study 28975600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 26355616 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 facial treatment
Number of subjects: 12
Study 26355616 — intervention group
Group type: COMPARATOR
Intervention: Microdermabrasion
Number of subjects: 12
Study 23271211 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 786
Study 23271211 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 786
Study 23271211 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of embryo transfer cycles
Number of subjects: 786
Study 20598758 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted leisure education program
Number of subjects: 49
Study 19584328 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with early-stage premenopausal breast cancer
Number of subjects: 19457
Study 19584328 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with early-stage postmenopausal breast cancer
Number of subjects: 19457
Study 19584328 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with advanced-stage ovarian cancer
Number of subjects: 19457
Study 19584328 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with advanced-stage prostate cancer
Number of subjects: 19457
Study 19584328 — intervention group
Group type: COMPARATOR
Intervention: All other patients (non-African American)
Number of subjects: 19457
Study 17058830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferulate (SF) 300 mg/d intravenously for 4 weeks
Number of subjects: 80
Study 17058830 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment including dietary therapy and hypodermic injection of insulin
Number of subjects: 80
Study 14762655 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day for 12 months
Number of subjects: 24
Study 14762655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11519354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide cream (generic drug)
Number of subjects: 20
Study 11519354 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide cream (brand name)
Number of subjects: 20
Study 11519354 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (no active treatment)
Number of subjects: 20
Study 9216708 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'DFUR + OK-432
Number of subjects: 50
Study 9216708 — intervention group
Group type: COMPARATOR
Intervention: OK-432
Number of subjects: 50
Study 9216708 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated)
Number of subjects: 50
Study 7853678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) administered at a dose of 60-90 mg/kg divided into 3 dosages via 30-minute intravenous drip infusion
Number of subjects: 17
Study 7853678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at a dose of 20 mg/kg via 30-minute intravenous drip infusion
Number of subjects: 17
Study 7853678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at a dose of 10 mg/kg via 30-minute intravenous drip infusion
Number of subjects: 17
Study 7853678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) at doses of 20 and 10 mg/kg via 30-minute intravenous infusion
Number of subjects: 17
Study 7853678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP) administered to patients with various infections
Number of subjects: 17
Study 7853678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefozopran (CZOP)
Number of subjects: 17
Study 3376911 — intervention group
Group type: EXPERIMENTAL
Intervention: High Mono diet (high in monounsaturates, low in cholesterol)
Number of subjects: 10
Study 3376911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Fat diet (low in fat, high in carbohydrates, low in cholesterol)
Number of subjects: 10